

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/521,338	01/12/2005	Olivier Dirat	T1587P	9128		
210 75	12/11/2006		EXAMINER			
MERCK AND CO., INC			LAMBKIN, DEBORAH C			
P O BOX 2000 RAHWAY, NJ 07065-0907			ART UNIT	PAPER NUMBER		
,				1625		
			DATE MAILED: 12/11/2006			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	tion No.	Applicant(s)		
Office Action Summary		10/521,	DIRAT ET AL.			
		Examin	er	Art Unit		
			C. Lambkin	1626		
	MAILING DATE of this commun	ication appears on t	he cover sheet with the c	orrespondence address		
WHICHEV - Extensions of after SIX (6) - If NO period - Failure to re Any reply re	ENED STATUTORY PERIOD F ER IS LONGER, FROM THE M of time may be available under the provisions MONTHS from the mailing date of this comm for reply is specified above, the maximum st ply within the set or extended period for reply ceived by the Office later than three months a nt term adjustment. See 37 CFR 1.704(b).	IAILING DATE OF T of 37 CFR 1.136(a). In no en nunication. atutory period will apply and will, by statute, cause the a	THIS COMMUNICATION Event, however, may a reply be tinwill expire SIX (6) MONTHS from application to become ABANDONE	N. nely filed the mailing date of this communi D (35 U.S.C. § 133).		
Status		•	•			
2a)∏ This 3)∏ Sinc	consive to communication(s) file action is FINAL . e this application is in condition ed in accordance with the practi	2b)⊠ This action is for allowance excep	non-final. ot for formal matters, pro		its is	
Disposition o	f Claims		·			
4a) C 5)	m(s) <u>22-40</u> is/are pending in the of the above claim(s) is/am(s) is/are allowed. m(s) <u>22-40</u> is/are rejected. m(s) is/are objected to. m(s) are subject to restrict	re withdrawn from c				
Application P	apers					
10)⊡ The ∈ Appl Repl	specification is objected to by the drawing(s) filed on is/are icant may not request that any objected to accement drawing sheet(s) including the path or declaration is objected to	: a) ☐ accepted or ction to the drawing(s g the correction is requ) be held in abeyance. Se uired if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.1		
Priority unde	r 35 U.S.C. § 119		•			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. DEBORANC LAMBK:N PRIMALE AMINER						
2) Notice of D 3) Information	deferences Cited (PTO-892) Praftsperson's Patent Drawing Review (I Disclosure Statement(s) (PTO/SB/08) Disclosure 1/12/05	PTO-948)	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	ate	Piall	

Application/Control Number: 10/521,338

Art Unit: 1626

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 22-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Owen et al (US 6,458,830).

Owen et al teaches the generic compound which not only cross embraces the instant generic compound but also have exemplified where R7 can be a substituted piperazine (see ex.134) providing the necessary motivation and guidance to make the instant piperazinone.

There is nothing unobvious in choosing a species from a prior art genus, motivation being that said species would be expected to possess the same or similar properties as their exemplified counterparts, in this case NK-1 receptor antagonists, absent some unobvious or unexpected results.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah C. Lambkin whose telephone number is 571-272-0698.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached on 571-272-0699.

Application/Control Number: 10/521,338

Art Unit: 1626

DEBORAH C. LAMBKIN C

Deborah C. Lambkin Primary Patent Examiner Art Unit 1626